News9 months ago
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of...